API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.
Lead Product(s): Fondaparinux Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Arixtra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Viatris
Deal Size: $757.2 million Upfront Cash: $310.4 million
Deal Type: Acquisition September 08, 2020